Rhythm's Imcivree has shown benefit in a Phase III trial in patients with acquired hypothalamic obesity, leading to 19.8% ...

a rare disease that leads to insatiable hunger. Both indications are genetically driven. An approval of Imcivree in hypothalamic obesity would be the first for this drug in an acquired form of ...

While pharma giants Novo Nordisk and Eli Lilly may have a solid hold on the obesity arena, Rhythm Pharmaceuticals is looking ...

Acquired hypothalamic obesity is a disease characterized by accelerated and sustained change in weight trajectory caused by an injury to the hypothalamus, often accompanied by hyperphagia ...

Acquired hypothalamic obesity is a disease characterized by accelerated and sustained change in weight trajectory caused by an injury to the hypothalamus, often accompanied by hyperphagia ...